Epidemiology of the contraceptive pill and venous thromboembolism

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Current users of combined oral contraceptives have an increased risk of venous thromboembolism. The risk appears to be higher during the first year of use and disappears rapidly once oral contraception is stopped. There is a strong interaction between hereditary defects of coagulation, combined oral contraceptive use and venous thromboembolism. Nevertheless, the routine screening of women before they use combined oral contraception is not recommended. Venous thromboembolism seems to be higher in overweight users, and after air, and possibly other forms of, travel. Both the oestrogen and progestogen content of combined oral contraceptives have been implicated in differences in venous thrombotic risk between products. Even if real, the absolute difference in risk between products is small, because the background incidence of venous thromboembolism in young women is low. All currently available combined oral contraceptives are safe. Progestogen-only oral contraceptives are not associated with an increased risk of venous thromboembolism. (C) 2011 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)S30-S34
Number of pages5
JournalThrombosis Research
Volume127
Issue numberSuppl. 3
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Venous Thromboembolism
Contraceptives, Oral, Combined
Contraceptive Agents
Epidemiology
Progestins
Contraception
Oral Contraceptives
Estrogens
Air
Incidence

Keywords

  • venous thromboembolism
  • pulmonary embolism
  • combined oral contraceptives
  • progestogen-only oral contraceptives
  • progestogens
  • oestrogens
  • review article

Cite this

Epidemiology of the contraceptive pill and venous thromboembolism. / Hannaford, Philip C.

In: Thrombosis Research, Vol. 127, No. Suppl. 3, 02.2011, p. S30-S34.

Research output: Contribution to journalArticle

@article{0dd5613cf3054840bda1691f0f0bcc57,
title = "Epidemiology of the contraceptive pill and venous thromboembolism",
abstract = "Current users of combined oral contraceptives have an increased risk of venous thromboembolism. The risk appears to be higher during the first year of use and disappears rapidly once oral contraception is stopped. There is a strong interaction between hereditary defects of coagulation, combined oral contraceptive use and venous thromboembolism. Nevertheless, the routine screening of women before they use combined oral contraception is not recommended. Venous thromboembolism seems to be higher in overweight users, and after air, and possibly other forms of, travel. Both the oestrogen and progestogen content of combined oral contraceptives have been implicated in differences in venous thrombotic risk between products. Even if real, the absolute difference in risk between products is small, because the background incidence of venous thromboembolism in young women is low. All currently available combined oral contraceptives are safe. Progestogen-only oral contraceptives are not associated with an increased risk of venous thromboembolism. (C) 2011 Elsevier Ltd. All rights reserved.",
keywords = "venous thromboembolism, pulmonary embolism, combined oral contraceptives, progestogen-only oral contraceptives, progestogens, oestrogens, review article",
author = "Hannaford, {Philip C.}",
year = "2011",
month = "2",
doi = "10.1016/S0049-3848(11)70009-3",
language = "English",
volume = "127",
pages = "S30--S34",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "Suppl. 3",

}

TY - JOUR

T1 - Epidemiology of the contraceptive pill and venous thromboembolism

AU - Hannaford, Philip C.

PY - 2011/2

Y1 - 2011/2

N2 - Current users of combined oral contraceptives have an increased risk of venous thromboembolism. The risk appears to be higher during the first year of use and disappears rapidly once oral contraception is stopped. There is a strong interaction between hereditary defects of coagulation, combined oral contraceptive use and venous thromboembolism. Nevertheless, the routine screening of women before they use combined oral contraception is not recommended. Venous thromboembolism seems to be higher in overweight users, and after air, and possibly other forms of, travel. Both the oestrogen and progestogen content of combined oral contraceptives have been implicated in differences in venous thrombotic risk between products. Even if real, the absolute difference in risk between products is small, because the background incidence of venous thromboembolism in young women is low. All currently available combined oral contraceptives are safe. Progestogen-only oral contraceptives are not associated with an increased risk of venous thromboembolism. (C) 2011 Elsevier Ltd. All rights reserved.

AB - Current users of combined oral contraceptives have an increased risk of venous thromboembolism. The risk appears to be higher during the first year of use and disappears rapidly once oral contraception is stopped. There is a strong interaction between hereditary defects of coagulation, combined oral contraceptive use and venous thromboembolism. Nevertheless, the routine screening of women before they use combined oral contraception is not recommended. Venous thromboembolism seems to be higher in overweight users, and after air, and possibly other forms of, travel. Both the oestrogen and progestogen content of combined oral contraceptives have been implicated in differences in venous thrombotic risk between products. Even if real, the absolute difference in risk between products is small, because the background incidence of venous thromboembolism in young women is low. All currently available combined oral contraceptives are safe. Progestogen-only oral contraceptives are not associated with an increased risk of venous thromboembolism. (C) 2011 Elsevier Ltd. All rights reserved.

KW - venous thromboembolism

KW - pulmonary embolism

KW - combined oral contraceptives

KW - progestogen-only oral contraceptives

KW - progestogens

KW - oestrogens

KW - review article

U2 - 10.1016/S0049-3848(11)70009-3

DO - 10.1016/S0049-3848(11)70009-3

M3 - Article

VL - 127

SP - S30-S34

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - Suppl. 3

ER -